Literature DB >> 19684400

Cognitive reserve in relation to abeta42 in patients converting from MCI to dementia - a follow-up report.

S Rolstad1, A Nordlund, C Eckerström, M H Gustavsson, H Zetterberg, A Wallin.   

Abstract

UNLABELLED: The concept of the cognitive reserve (CR) hypothesizes that premorbid factors such as education enable compensation for the manifestation of brain pathology. Accordingly, pathology should be more prominent in individuals with higher CR before becoming clinically apparent. Previously, we found that patients subsequently converting to dementia with higher CR had lower concentrations of amyloid beta 42 (abeta42) as compared to patients with lower CR. However, the interaction between time, biomarkers, neuropsychological performance and CR is yet to be established.
OBJECTIVE: To study the relation between biomarkers, neuropsychological performance and CR longitudinally.
METHOD: A mixed between-within subject analysis of variance was performed for longitudinal analysis. Paired t tests were used for within group comparisons.
RESULTS: Patients with higher CR (n = 15) had significantly lower concentrations of abeta42 at both time points compared to those with medium (n = 23) and lower CR (n = 28). Also, abeta42 concentrations decreased significantly from baseline to follow-up in patients with higher and medium CR. Groups performed comparably on neuropsychological tests.
CONCLUSION: This study provides further support for the applicability of abeta42 as a substitute for pathology in relation to CR. Also, abeta42 reflects the disease progression in patients with higher and medium CR.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19684400     DOI: 10.1159/000234912

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  7 in total

1.  Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease.

Authors:  Rodrigo P Almeida; Stephanie A Schultz; Benjamin P Austin; Elizabeth A Boots; N Maritza Dowling; Carey E Gleason; Barbara B Bendlin; Mark A Sager; Bruce P Hermann; Henrik Zetterberg; Cynthia M Carlsson; Sterling C Johnson; Sanjay Asthana; Ozioma C Okonkwo
Journal:  JAMA Neurol       Date:  2015-06       Impact factor: 18.302

2.  Relationship of cognitive reserve and cerebrospinal fluid biomarkers to the emergence of clinical symptoms in preclinical Alzheimer's disease.

Authors:  Anja Soldan; Corinne Pettigrew; Shanshan Li; Mei-Cheng Wang; Abhay Moghekar; Ola A Selnes; Marilyn Albert; Richard O'Brien
Journal:  Neurobiol Aging       Date:  2013-08-01       Impact factor: 4.673

3.  How the cognitive reserve interacts with β-amyloid deposition in mitigating FDG metabolism: An observational study.

Authors:  Elena Carapelle; Laura Serra; Sergio Modoni; Michele Falcone; Carlo Caltagirone; Marco Bozzali; Luigi Maria Specchio; Carlo Avolio
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

4.  Better prognostic accuracy in younger mild cognitive impairment patients with more years of education.

Authors:  Mattias Göthlin; Marie Eckerström; Sindre Rolstad; Petronella Kettunen; Anders Wallin
Journal:  Alzheimers Dement (Amst)       Date:  2018-06-08

Review 5.  Alzheimer's disease--subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies.

Authors:  Anders Wallin; Arto Nordlund; Michael Jonsson; Kaj Blennow; Henrik Zetterberg; Annika Öhrfelt; Jacob Stålhammar; Marie Eckerström; Mårten Carlsson; Erik Olsson; Mattias Göthlin; Johan Svensson; Sindre Rolstad; Carl Eckerström; Maria Bjerke
Journal:  J Cereb Blood Flow Metab       Date:  2016-01       Impact factor: 6.200

6.  Cognitive reserve and Aβ1-42 in mild cognitive impairment (Argentina-Alzheimer's Disease Neuroimaging Initiative).

Authors:  Paula Harris; Marcos Fernandez Suarez; Ezequiel I Surace; Patricio Chrem Méndez; María Eugenia Martín; María Florencia Clarens; Fernanda Tapajóz; Maria Julieta Russo; Jorge Campos; Salvador M Guinjoan; Gustavo Sevlever; Ricardo F Allegri
Journal:  Neuropsychiatr Dis Treat       Date:  2015-10-07       Impact factor: 2.570

Review 7.  Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Craig Ritchie; Nadja Smailagic; Anna H Noel-Storr; Yemisi Takwoingi; Leon Flicker; Sam E Mason; Rupert McShane
Journal:  Cochrane Database Syst Rev       Date:  2014-06-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.